Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs

Víctor R. De Jesús, Barbara W. Adam, Daniel Mandel, Carla D. Cuthbert, Dietrich Matern

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Tyrosinemia type I (TYR I) is caused by autosomal recessive fumarylacetoacetate hydrolase deficiency and is characterized by development of severe liver disease in infancy and neurologic crises. If left untreated, most patients die of liver failure in the first years of life. Intervention with medication is effective when initiated during the first month of life. This improvement in the treatment of TYR I patients influenced the decision to include TYR I in the US Secretary of the Department of Health and Human Services' (HHS) Recommended Uniform Screening Panel. However, while tyrosine is routinely measured in newborn screening (NBS) by tandem mass spectrometry (MS/MS), elevated tyrosine levels are not specific to TYR I. To improve the specificity of NBS for TYR I, several assays were developed to measure succinylacetone (SUAC) in dried blood spots (DBS). SUAC is a pathognomonic marker of TYR I, and its detection by NBS MS/MS is possible. This review of the current status of NBS for TYR I in the US is the result of discussions at the HHS Secretary's (Discretionary) Advisory Committee on Heritable Disorders in Newborns and Children about the inconsistent implementation of effective NBS for TYR I in the US. We sought to understand the different TYR I screening practices in US NBS programs. Results indicate that 50 out of 51 NBS programs in the US screen for TYR I, and a successful SUAC performance evaluation scheme is available from the Centers for Disease Control and Prevention. Programmatic and methodological barriers were identified that prevent widespread adoption of SUAC measurements in NBS laboratories. However, since SUAC detection is currently the best approach to NBS for TYR I, a further delay of the addition of SUAC measurement into NBS procedures is discouraged. SUAC measurement should improve both the false positive and false negative rate in NBS for TYR I thereby yielding the desired benefits for affected patients at no expense to the overall population served.

Original languageEnglish (US)
Pages (from-to)67-75
Number of pages9
JournalMolecular Genetics and Metabolism
Volume113
Issue number1
DOIs
StatePublished - Sep 1 2014

Fingerprint

Tyrosinemias
Screening
Newborn Infant
Tyrosine
Liver
succinylacetone
United States Dept. of Health and Human Services
Health
Disease control
Liver Failure
Advisory Committees
Centers for Disease Control and Prevention (U.S.)
Tandem Mass Spectrometry
Nervous System
Health Services

Keywords

  • HHS secretary's (discretionary) advisory committee on heritable disorders in newborns and children
  • Newborn screening
  • Succinylacetone
  • Tyrosine
  • Tyrosinemia type I
  • US recommended uniform screening panel

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs. / De Jesús, Víctor R.; Adam, Barbara W.; Mandel, Daniel; Cuthbert, Carla D.; Matern, Dietrich.

In: Molecular Genetics and Metabolism, Vol. 113, No. 1, 01.09.2014, p. 67-75.

Research output: Contribution to journalArticle

De Jesús, Víctor R. ; Adam, Barbara W. ; Mandel, Daniel ; Cuthbert, Carla D. ; Matern, Dietrich. / Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs. In: Molecular Genetics and Metabolism. 2014 ; Vol. 113, No. 1. pp. 67-75.
@article{73b08dc06281428fb5d02128a145cdf3,
title = "Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs",
abstract = "Tyrosinemia type I (TYR I) is caused by autosomal recessive fumarylacetoacetate hydrolase deficiency and is characterized by development of severe liver disease in infancy and neurologic crises. If left untreated, most patients die of liver failure in the first years of life. Intervention with medication is effective when initiated during the first month of life. This improvement in the treatment of TYR I patients influenced the decision to include TYR I in the US Secretary of the Department of Health and Human Services' (HHS) Recommended Uniform Screening Panel. However, while tyrosine is routinely measured in newborn screening (NBS) by tandem mass spectrometry (MS/MS), elevated tyrosine levels are not specific to TYR I. To improve the specificity of NBS for TYR I, several assays were developed to measure succinylacetone (SUAC) in dried blood spots (DBS). SUAC is a pathognomonic marker of TYR I, and its detection by NBS MS/MS is possible. This review of the current status of NBS for TYR I in the US is the result of discussions at the HHS Secretary's (Discretionary) Advisory Committee on Heritable Disorders in Newborns and Children about the inconsistent implementation of effective NBS for TYR I in the US. We sought to understand the different TYR I screening practices in US NBS programs. Results indicate that 50 out of 51 NBS programs in the US screen for TYR I, and a successful SUAC performance evaluation scheme is available from the Centers for Disease Control and Prevention. Programmatic and methodological barriers were identified that prevent widespread adoption of SUAC measurements in NBS laboratories. However, since SUAC detection is currently the best approach to NBS for TYR I, a further delay of the addition of SUAC measurement into NBS procedures is discouraged. SUAC measurement should improve both the false positive and false negative rate in NBS for TYR I thereby yielding the desired benefits for affected patients at no expense to the overall population served.",
keywords = "HHS secretary's (discretionary) advisory committee on heritable disorders in newborns and children, Newborn screening, Succinylacetone, Tyrosine, Tyrosinemia type I, US recommended uniform screening panel",
author = "{De Jes{\'u}s}, {V{\'i}ctor R.} and Adam, {Barbara W.} and Daniel Mandel and Cuthbert, {Carla D.} and Dietrich Matern",
year = "2014",
month = "9",
day = "1",
doi = "10.1016/j.ymgme.2014.07.010",
language = "English (US)",
volume = "113",
pages = "67--75",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs

AU - De Jesús, Víctor R.

AU - Adam, Barbara W.

AU - Mandel, Daniel

AU - Cuthbert, Carla D.

AU - Matern, Dietrich

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Tyrosinemia type I (TYR I) is caused by autosomal recessive fumarylacetoacetate hydrolase deficiency and is characterized by development of severe liver disease in infancy and neurologic crises. If left untreated, most patients die of liver failure in the first years of life. Intervention with medication is effective when initiated during the first month of life. This improvement in the treatment of TYR I patients influenced the decision to include TYR I in the US Secretary of the Department of Health and Human Services' (HHS) Recommended Uniform Screening Panel. However, while tyrosine is routinely measured in newborn screening (NBS) by tandem mass spectrometry (MS/MS), elevated tyrosine levels are not specific to TYR I. To improve the specificity of NBS for TYR I, several assays were developed to measure succinylacetone (SUAC) in dried blood spots (DBS). SUAC is a pathognomonic marker of TYR I, and its detection by NBS MS/MS is possible. This review of the current status of NBS for TYR I in the US is the result of discussions at the HHS Secretary's (Discretionary) Advisory Committee on Heritable Disorders in Newborns and Children about the inconsistent implementation of effective NBS for TYR I in the US. We sought to understand the different TYR I screening practices in US NBS programs. Results indicate that 50 out of 51 NBS programs in the US screen for TYR I, and a successful SUAC performance evaluation scheme is available from the Centers for Disease Control and Prevention. Programmatic and methodological barriers were identified that prevent widespread adoption of SUAC measurements in NBS laboratories. However, since SUAC detection is currently the best approach to NBS for TYR I, a further delay of the addition of SUAC measurement into NBS procedures is discouraged. SUAC measurement should improve both the false positive and false negative rate in NBS for TYR I thereby yielding the desired benefits for affected patients at no expense to the overall population served.

AB - Tyrosinemia type I (TYR I) is caused by autosomal recessive fumarylacetoacetate hydrolase deficiency and is characterized by development of severe liver disease in infancy and neurologic crises. If left untreated, most patients die of liver failure in the first years of life. Intervention with medication is effective when initiated during the first month of life. This improvement in the treatment of TYR I patients influenced the decision to include TYR I in the US Secretary of the Department of Health and Human Services' (HHS) Recommended Uniform Screening Panel. However, while tyrosine is routinely measured in newborn screening (NBS) by tandem mass spectrometry (MS/MS), elevated tyrosine levels are not specific to TYR I. To improve the specificity of NBS for TYR I, several assays were developed to measure succinylacetone (SUAC) in dried blood spots (DBS). SUAC is a pathognomonic marker of TYR I, and its detection by NBS MS/MS is possible. This review of the current status of NBS for TYR I in the US is the result of discussions at the HHS Secretary's (Discretionary) Advisory Committee on Heritable Disorders in Newborns and Children about the inconsistent implementation of effective NBS for TYR I in the US. We sought to understand the different TYR I screening practices in US NBS programs. Results indicate that 50 out of 51 NBS programs in the US screen for TYR I, and a successful SUAC performance evaluation scheme is available from the Centers for Disease Control and Prevention. Programmatic and methodological barriers were identified that prevent widespread adoption of SUAC measurements in NBS laboratories. However, since SUAC detection is currently the best approach to NBS for TYR I, a further delay of the addition of SUAC measurement into NBS procedures is discouraged. SUAC measurement should improve both the false positive and false negative rate in NBS for TYR I thereby yielding the desired benefits for affected patients at no expense to the overall population served.

KW - HHS secretary's (discretionary) advisory committee on heritable disorders in newborns and children

KW - Newborn screening

KW - Succinylacetone

KW - Tyrosine

KW - Tyrosinemia type I

KW - US recommended uniform screening panel

UR - http://www.scopus.com/inward/record.url?scp=84908508158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908508158&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2014.07.010

DO - 10.1016/j.ymgme.2014.07.010

M3 - Article

VL - 113

SP - 67

EP - 75

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 1

ER -